Efficacy of alphas1-casein hydrolysate on stress-related symptoms in women

To examine the effects of alpha (s1)-casein hydrolysate on females with stress-related symptoms. Double-blind, randomized, crossover, placebo-controlled trial. The alpha (s1)-casein hydrolysate was manufactured by INGREDIA (Arras, France) and the placebo was manufactured by DIETAROMA (Bourg, France)...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical nutrition 2007-04, Vol.61 (4), p.536-541
Main Authors: Kim, J H, Desor, D, Kim, Y T, Yoon, W J, Kim, K S, Jun, J S, Pyun, K H, Shim, I
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anxiety - drug therapy
Anxiety - etiology
Cardiovascular Physiological Phenomena - drug effects
Caseins - therapeutic use
Cross-Over Studies
Dietary Supplements
Digestion - drug effects
Double-Blind Method
Female
Humans
Middle Aged
Severity of Illness Index
Sleep Wake Disorders - drug therapy
Sleep Wake Disorders - etiology
Stress, Psychological - drug therapy
Stress, Psychological - physiopathology
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To examine the effects of alpha (s1)-casein hydrolysate on females with stress-related symptoms. Double-blind, randomized, crossover, placebo-controlled trial. The alpha (s1)-casein hydrolysate was manufactured by INGREDIA (Arras, France) and the placebo was manufactured by DIETAROMA (Bourg, France). Study was designed and performed at PROCLAIM (Rennes, France), and the statistical analyses were performed by D Desor (Nancy, France). A total of 63 female volunteers suffering from at least one disorder that may be related to stress such as anxiety, sleep problems and general fatigue. A total of 63 volunteers participated in a double-blind, randomized, crossover, placebo-controlled study. Subjects were randomly allocated to receive either tablets containing alpha (s1)-casein hydrolysate or placebo at the dose of 150 mg/day for 30 days. After a 3 weeks washout period, they were crossed over for a new 30-day period of tablets intake. The outcome measure was a questionnaire including 44 items of symptoms that may be related stress in which the severity of each sign was evaluated using a 10-degree scale. These measures were studied repeatedly at the day of 0, 15 and 30 after the start of each interventional period. The 30-day treatment by alpha (s1)-casein hydrolysate in females with stress-related symptoms reduced their symptoms, particularly in digestion (P
ISSN:0954-3007